The forecast for antiinfective medicine sales in Sweden from 2024 to 2028 shows a flat trajectory, with each year maintaining a steady value of 6.2% of total sales. There is no expected year-on-year variation in percentage, indicating a stable market without growth or decline projections.
Given that we are in 2024, it is important to note the actual data from 2023 to offer a comparison, although the dataset provided does not include the 2023 value. Assuming the 2023 value aligned closely with the subsequent forecast, the compound annual growth rate (CAGR) over the last five years would remain minimal or zero due to the lack of variation.
Future trends to watch for in the antiinfective medicine market in Sweden include potential impacts of emerging infectious diseases, advancements in medical research, and increased government or private sector investment in healthcare. These factors could introduce variability to the otherwise stable market forecasts.
